Unusual 11 Mid-Day Movers 10/25: (CWEI) (NXTD) (EYES) Higher; (DPRX) (CRBP) (CALA) Lower (more...)

October 25, 2016 1:34 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Unusual 11 Mid-Day Movers

Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) 78% LOWER; announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study. Neither trial met the secondary endpoint of demonstrating a higher rate of eradication of bacteria for the Locilex arm. While the overall adverse event incidence was comparable to vehicle alone, serious adverse events with Locilex included higher than anticipated osteomyelitis and cellulitis in the Locilex arm of each study.

Corbus Pharma (NASDAQ: CRBP) 28.1% LOWER; was mentioned cautiously in an article by Adam Feuerstein. According to to the report, an unnamed fund manager who is short the stock said the company's only pipeline drug, Resunab, doesn't work.

Clayton Williams Energy, Inc. (NYSE: CWEI) 25.5% HIGHER; announced that it has entered into a definitive purchase and sale agreement with a third party to sell substantially all of the Company's assets in the Giddings Area in East Central Texas for a sale price of $400 million. The sale is subject to customary closing conditions and adjustments. The Company expects to close the sale in December 2016 and use the proceeds from the sale to fund development in the Delaware Basin and repay a portion of its outstanding indebtedness.

NXT-ID (NASDAQ: NXTD) 21.6% LOWER; sees added gains on heavy volume

Calithera Biosciences (NASDAQ: CALA) 21.2% LOWER; Citi initiated coverage with a Sell rating and a price target of $1.00.

Towerstream Corporation (Nasdaq: TWER) 20.4% HIGHER; expects to add 100 new buildings to its On-Net footprint in Q4 to 437 total buildings. This is more than double the 265 that were in the On-Net footprint at the end of H1.

Sonic Corp (NASDAQ: SONC) 17.8% LOWER; reported Q4 EPS of $0.45, $0.01 better than the analyst estimate of $0.44. Revenue for the quarter came in at $162.1 million versus the consensus estimate of $167.15 million. While the macroeconomic environment may impact results, the company expects adjusted earnings per share for fiscal year 2017 to be in the range of down 7% to flat year over year.

Second Sight Medical Products, Inc. (NASDAQ: EYES) 16.2% HIGHER; announced the first successful implantation and activation of a wireless visual cortical stimulator in a human subject, providing the initial human proof of concept for the ongoing development of the Companys Orion I Visual Cortical Prosthesis (Orion I). In the UCLA study supported by Second Sight, a 30 year old patient was implanted with a wireless multichannel neurostimulation system on the visual cortex and was able to perceive and localize individual phosphenes or spots of light with no significant adverse side effects.

SAExploration Holdings, Inc. (Nasdaq: SAEX) 15.4% HIGHER; announced that it has received approximately $24.4 million of tax credit certificates from the state of Alaskas Department of Revenue. SAE further announced that as a result of receiving these tax credit certificates, and having substantially satisfied the conditional requirements under its senior term loan facility (the Senior Loan Facility), it has been granted access to the remaining $15.0 million of funding available under its Senior Loan Facility.

Nielsen Holdings (NYSE: NLSN) 14.7% LOWER; reported Q3 EPS of $0.74, $0.02 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.59 billion. GUIDANCE: Nielsen Holdings sees FY2016 EPS of $2.73-$2.79, versus the consensus of $2.87.

Under Armour (NYSE: UA) 13.3% LOWER; reported Q3 EPS of $0.29, $0.04 better than the analyst estimate of $0.25. Revenue for the quarter came in at $1.47 billion versus the consensus estimate of $1.46 billion. sees Q4 revenue up about 20 percent, gross margin relatively unchanged, and operating income in the range of $186 - $191 million. Revenue is expected to be up 20 percent, versus consensus expectations of 22 percent growth. The company is targeting revenue growth consistently in the low-20 percent rage for FY17/FY18. Operating income is expected to be up in the mid-teens range over the next two years. The company says it is on track to achieve revenue of $7.5 billion in FY18.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Citi, Unusual 11 Mid-Day Movers, Earnings, Adam Feuerstein

Add Your Comment